Next Jump

Amgen is a global leader in biotechnology, dedicated to the development of innovative biologic medicines that address serious illnesses, particularly in areas with limited treatment options. The company's mission encompasses a commitment to scientific advancement, patient safety, and corporate responsibility, reflecting its core values of integrity and excellence. With a strong focus on research and development, Amgen employs cutting-edge technologies, including AI and data science, to optimize clinical trials and enhance drug design. The company also prioritizes community investment, diversity, and sustainability, striving to make a positive impact on healthcare access and health equity worldwide. Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

Dragonfly Therapeutics, located in Cambridge, MA, is a clinical-stage biotech company dedicated to transforming the treatment of various diseases through innovative natural killer cell-based therapies. With proprietary platforms including TriNKETs and CYTOKINEs, Dragonfly has developed a robust pipeline with a focus on autoimmune diseases, oncology, and neuro-inflammation, targeting significant patient needs. The company has formed strategic collaborations with industry leaders like AbbVie, BMS, Gilead, and Merck, leading to the advancement of 11 drug candidates. Dragonfly aims to continuously grow its pipeline, augmenting its research in a range of therapeutic areas, including fibrotic diseases and infectious diseases, to ensure improved patient outcomes. Generated from the website